ISSN 2149-3235 | E-ISSN 2149-3057
Original Article
Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival
1 Department of Medical Oncology, Gaziantep University School of Medicine, Gaziantep, Turkey  
Turk J Urol 2017; 43: 273-278
DOI: 10.5152/tud.2017.24478
Key Words: Bladder cancer; gemcitabine; maintenance therapy; metastasis.

Objective: To investigate the effects of gemcitabine maintenance treatment on survival in patients with metastatic bladder cancer.


Material and methods: Gemcitabine maintenance monotherapy was administered following the standard platinum-gemcitabine therapy in patients with metastatic bladder cancer. Patients who had responded to standard treatment received maintenance gemcitabine therapy as 1000 mg/m2 on days 1 and 8 every three weeks until progression or development of unacceptable toxicity. The following clinical factors were noted: performance status, age, sex, stage, site of metastasis, choice of cisplatin-gemcitabine or carboplatin-gemcitabine, response rates to the initial chemotherapy. Progression- free survival (PFS) and overall survival (OS) for standard treatment, and following gemcitabine monotreatment and for maintenance gemcitabine therapy were calculated using Kaplan–Meier method.


Results: A total of 88 patients with metastatic bladder cancer treated between February 2009 to October 2015 were evaluated retrospectively and 23 patients (26.1%) who had responded to six cycles of platinum-gemcitabine treatment were included in this study. Maintenance gamcitabine was administered for a median of 7 times (range 3–14 times). Grade 3 hematotoxicity according to the criteria of the Common Terminology Criteria of Adverse Events was observed in 7 (30.4%) patients. Median PFS of patients was 46 (range: 30-82) weeks for platinum-based treatment plus maintenance gemcitabine therapy. A higher median PFS was obtained in patients who were <65 year-olds, without organ metastasis with objective response rate, however, it was statistically insignificant.


Conclusion: Gemcitabine maintenance therapy in metastatic bladder cancer patients who did not shown progression after the standard platinum-gemcitabine treatment contributes to survival and presents low toxicity profile, when compared to historical controls.


Cite this article as: Kuş T, Aktaş G. Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival. Turk J Urol 2017; 43: 273-8

Key Words
AVES | Copyright © 2018 Turkish Association of Urology | Latest Update: 07.09.2018